[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0983303B1 - Procede de production de proteines non immunogenes - Google Patents

Procede de production de proteines non immunogenes Download PDF

Info

Publication number
EP0983303B1
EP0983303B1 EP98922932A EP98922932A EP0983303B1 EP 0983303 B1 EP0983303 B1 EP 0983303B1 EP 98922932 A EP98922932 A EP 98922932A EP 98922932 A EP98922932 A EP 98922932A EP 0983303 B1 EP0983303 B1 EP 0983303B1
Authority
EP
European Patent Office
Prior art keywords
cell epitopes
protein
sequence
cell
streptokinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP98922932A
Other languages
German (de)
English (en)
Other versions
EP0983303A1 (fr
Inventor
Francis Joseph Carr
Graham Biovation Limited CARTER
Anita Anne Biovation Limited Hamilton
Fiona Suzanne Biovation Limited ADAIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovation Ltd
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9710480.6A external-priority patent/GB9710480D0/en
Priority claimed from GBGB9716197.0A external-priority patent/GB9716197D0/en
Priority claimed from GBGB9725270.4A external-priority patent/GB9725270D0/en
Priority claimed from GBGB9807751.4A external-priority patent/GB9807751D0/en
Application filed by Biovation Ltd filed Critical Biovation Ltd
Priority to EP06004562.2A priority Critical patent/EP1724282B1/fr
Publication of EP0983303A1 publication Critical patent/EP0983303A1/fr
Application granted granted Critical
Publication of EP0983303B1 publication Critical patent/EP0983303B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to the production of substantially non-immunogenic proteins, for the generation of novel therapeutic and in vivo diagnostic agents for particular use in man.
  • the invention especially relates to a novel de-immunised version of the bacterial protein streptokinase.
  • the present invention details a process whereby potentially immunogenic epitopes within a non-autologous protein may be identified and offers methodology whereby such epitopes may be eliminated.
  • the therapeutic protein streptokinase is analysed for the presence of potential MHC binding motifs and a method disclosed for the removal of a number of these from the molecule.
  • Streptokinase is a single chain protein of approximate molecular weight 47kDa that is produced by certain strains of ⁇ -haemolytic streptococci (Huang T.T. et al ., Mol. Biol. 2 197-205 (1989)).
  • the protein has no inherent enzymatic activity but has considerable clinical importance owing to its ability to efficiently bind human plasminogen, potentiating its activation to plasmin and thereby promoting the dissolution of fibrin filaments in blood clots.
  • SK is an effective thrombolytic agent in the treatment of coronary thrombosis, improving survival (ISIS-2 Collaborative Group, Lancet 2 349-360 (1988)) and preserving left ventricular function following myocardial infarction [ISAM Study Group, N. Engl. J. Med. 314 1465-1471 (1986); Kennedy J. W. et al., Circulation 77 345-352 (1988)).
  • ISIS-2 Collaborative Group Lancet 2 349-360 (1988)
  • ISIS-2 Collaborative Group Lancet 2 349-360 (1988)
  • preserving left ventricular function following myocardial infarction ISIS-2 Collaborative Group, Lancet 2 349-360 (1988)
  • ISIS-2 Collaborative Group Lancet 2 349-360 (1988)
  • left ventricular function following myocardial infarction
  • the present invention provides, for the first time, a general method for creating substantially non-immunogenic proteins such as the bacterial protein streptokinase.
  • a streptokinase or part of the protein, non-immunogenic, or less immunogenic comprising:
  • the present invention could also be applied to produce therapeutic proteins other than streptokinase. Proteins which would otherwise be immunogenic in man could be de-immunised by removal of T cell epitopes.
  • the B cell epitopes could additionally be removed from the protein by substituting surface amino from the reference human protein in place of the corresponding amino acids in the non-human or potentially immunogenic protein.
  • clinical use of the thrombolytic agent bacterial streptokinase is limited by human immune responses against the molecule; such molecules could be engineered to remove potential T cell epitopes in order to remove the immunogenicity.
  • the invention will be used to reduce the immunogenicity of a protein or part thereof of a first species in relation to the immune system of a second species.
  • the first species may be non-human, and the second species may be human.
  • Examples of typical non-human species useful in relation to embodiments of the invention relating to immunoglobulins include mammals, especially rodents such as rats and, in particular, mice, and farm animals such as sheep and cattle.
  • the first species may be taxonomically far removed from the second species; when the first species is non-human, it may be non-mammalian and even non-eukaryotic.
  • the invention also relates to species other than man and to proteins, particularly therapeutic proteins, generally, including specific binding molecules other than whole antibodies.
  • the method of the invention is based on the consideration of how an immune response against a protein is usually created in humans as the basis for avoiding or eliminating sequences within the protein which are involved in this immune response.
  • a therapeutic protein When a therapeutic protein is administered to a human patient, the protein is subjected to surveillance by both the humoral and cellular arms of the immune system which will respond to the protein if it is recognised as foreign and if the immune system is not already tolerant to the immunogenic sequence within the protein.
  • immature B-cells displaying surface immunoglobulins can bind to one or more sequences within the therapeutic protein ("B-cell epitopes") if there is an affinity fit between the an individual sIg and the B-cell epitope and if the B-cell epitope is exposed such that sIg can access the B-cell epitope.
  • B-cell epitopes sequences within the therapeutic protein
  • the process of sIg binding to the therapeutic protein can, in the presence of suitable cytokines, stimulate the B-cell to differentiate and divide to provide soluble forms of the original sIg which can complex with the therapeutic protein to limit its effertiveness and facilitate its clearance from the patient.
  • An effective T-cell response requires the uptake of the therapeutic protein by antigen-presenting cells (APCs) which can include B-cells themselves or other professional APCs such as macrophages, dendritic cells and other monocytes.
  • APCs antigen-presenting cells
  • non-professional APCs such as the cells to which the protein binds can take up the therapeutic protein and provide intermediate processing of the protein such that professional APCs can then absorb the protein components.
  • APCs can then present suitable peptides from the therapeutic protein ("T-cell epitopes”) complexed with MHC class II molecules at the cell surface.
  • Such peptide-MHC class II complexes can be recognised by helper T-cells via the T-cell receptor and this results in stimulation of the T-cells and secretion of cytokines which provides "help" for B-cells in their differentiation to full antibody producing cells.
  • helper T-cells via the T-cell receptor and this results in stimulation of the T-cells and secretion of cytokines which provides "help" for B-cells in their differentiation to full antibody producing cells.
  • the T-cell response can also result in deleterious effects on the patient for example through inflammation and allergic reactions.
  • An effective primary immunogenic response to a therapeutic protein therefore usually requires a combination of B- and T-cell responses to B- and T-cell epitopes. Therefore, avoidance of a primary immunogenic response requires the avoidance or elimination of both B- and T-cell epitopes within the therapeutic protein. Without either the B- or T-cell response, the primary immunogenic response to a therapeutic protein is likely to be muted or absent.
  • the present invention therefore provides methods for avoiding or eliminating T-cell epitopes, or a combination of both B- and T-cell epitopes, from therapeutic proteins in order to create substantially non-immunogenic proteins with particular emphasis on avoiding such epitopes in the therapeutic protein.
  • the method takes advantage of the fact sIg can only bind to accessible regions of the therapeutic protein, i.e. sequences of exposed surface amino acids.
  • sequences of overlapping peptides within the therapeutic protein are analysed, in order to identify putative peptides suitable for presentation by MHC class II molecules.
  • a preferred method of the present invention therefore combines the removal of both B- and T-cell epitopes from a therapeutic protein, a process which is termed "de-immunisation”.
  • the present invention provides for removal of human (or other second species) T-cell epitopes from the therapeutic protein whereby the protein sequence can be analysed for the presence of MHC class II-binding motifs by any suitable means. For example, a comparison may be made with databases of MHC-binding motifs such as, for example by searching the "motifs" database at the world-wide web site wehil.wehi.edu.au . Alternatively, MHC class II-binding peptides may be identified using computational threading methods such as those devised by Altuvia et al. ( J. Mol. Biol. 249 244-250 (1995)) whereby consecutive overlapping peptides from the protein sequences are testing for their binding energies to MHC class II proteins.
  • these epitopes are then eliminated by alteration of one or more amino acids, as required to eliminate the T-cell epitope.
  • alteration of one or more amino acids within the T-cell epitope itself This could involve altering an amino acid adjacent the epitope in terms of the primary structure of the protein or one which is not adjacent in the primary structure but is adjacent in the secondary structure of the molecule.
  • the usual alteration contemplated will be amino acid substitution, but it is possible that in certain circumstances amino acid addition or deletion will be appropriate.
  • T-cell epitopes In order to minimise the creation of additional T-cell epitopes during the elimination of potential T-cell epitopes from the therapeutic protein sequence, the elimination of T-cell epitopes is preferably (but not necessarily) achieved by conversion to second species (usually human) germ-line amino acids at positions corresponding to those of the first species (usually mouse) amino acids within T-cell epitopes.
  • second species usually human
  • first species usually mouse
  • the de-immunised sequence may be analysed again to ensure that new T-cell epitopes have not been created and, if they have, the epitope(s) can be deleted, as described above; or the previous conversion to a corresponding human germ-line amino acid is altered by conversion of the murine (or other first species) amino acid to a similar non-human (or non-second species) amino acid (i.e. having similar size and/or charge, for example) until all T-cell epitopes are eliminated.
  • the present invention relates principally to therapeutic proteins from which human B- and T-cell epitopes have been deleted, it will be recognised that the removal of T-cell epitopes alone might, in some cases, also be effective in avoiding an immunogenic response in patients.
  • a I de-immunised streptokinase molecule which has been prepared by a method in accordance with the invention, for use in medicine or diagnosis.
  • a streptokinase molecule having the protein sequence of Figure 2.
  • the invention further extends to a method of treating or preventing a disease or condition, the method comprising administering to a subject an effective amount of said molecule prepared by a method in accordance with the the invention.
  • the following example was used to identify potential MHC class II binding motifs in streptokinase.
  • the sequence of streptokinase was identified from the GenBank database.
  • the sequence with accession number S46536 was used throughout ( Figure 28).
  • the sequence was analysed for the presence of potential MHC class II binding motifs by computer aided comparison to a database of MHC-binding motifs as resident on world wide web site wehil.wehi.edu.au.
  • results of the "searching" process indicate the presence of 395 potential MHC class II binding motifs.
  • 283 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences.
  • These epitopes were not considered further on the basis that immune responses in general are not mounted to autologous circulating proteins such as immunoglobulins. This implies immunological tolerance to the potential T-cell epitopes present in the structure of the immunoglobulins (and indeed the majority of human proteins).
  • Epitopes presented by non-autologous proteins such as SK which are identical or similar to motifs present in immunoglobulin proteins are likely also to be tolerated and in practice may be retained through the de-immunisation process.
  • LxxxAxxxxL identifies >4000 entries in a human protein sub-set of the SwissProt database, including serum albumin protein (SwissProt accession number P02768).
  • An example of an epitope where no match to a human protein considered to be in the general circulation was found is provided by sequence Y VD V N TN at position 299-305 in the SK protein. This sequence represents a potential epitope for presentation by HLA-DR4*0401.
  • Consensus sequence searching identifies ⁇ 50 human proteins containing this motif, of which many are intracellular proteins of differentiated tissues such as brain.
  • HLA-DR1*0101 binding motif was identified in the SK peptide sequence KADLLKAI at positions 76-83 of the SK protein. This motif identifies ⁇ 150 human proteins in the same data set and was also identified for modification by the method of the present invention.
  • PCR primers SK1 (5'-ggaattcatgattgctggacctgagtggctg) and SK2 (5'-tggatccttatttgtcgttagggtatc) were used to amplify the wild-type SK gene from a strain of Streptococcus equisimililis group C (ATCC accession number 9542).
  • the resulting 1233bp fragment was cloned into pUC19 as a BamHI-EcoRI restriction fragment using standard techniques (Sambrook J., Fritisch E. F. & Maniatis T.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (7)

  1. Procédé consistant à rendre une streptokinase non immunogène ou moins immunogène lorsqu'elle est exposée au système immunitaire d'une espèce humaine donnée, le procédé comprenant:
    (a) la détermination au moins en partie de la séquence des acides aminés de streptokinase;
    (b) l'identification d'un premier jeu d'un ou de plusieurs déterminants antigéniques de cellule T potentiels dans la séquence des acides aminés de streptokinase en (i) analysant quant à un chevauchement des séquences peptides à l'intérieur de ladite séquence des acides aminés, qui soit se lient à des molécules MHC classe II, soit présentent la capacité de stimuler des cellules T via une présentation sur MHC classe II, quant à la présence de motifs de liaison MHC classe II, et en (ii) comparant lesdites séquences avec des motifs de liaison MHC classe II humains disponibles à partir de bases de données de MHC,
    (c) l'identification d'un second jeu d'un ou de plusieurs déterminants antigéniques de cellule T potentiels comprenant un nombre réduit de motifs de cellule T par soustraction de déterminants antigéniques de cellule T potentiels dudit premier jeu, qui sont également présents dans des séquences de lignée germinale de régions variables d'immunoglobuline humaine qui sont obtenues à partir de bases de données de lignée germinales humaine, et
    (d) l'élimination de la séquence des acides aminés de streptokinase d'au moins l'un desdits déterminants antigéniques de cellule T identifiés conformément à l'étape c) par altération d'un ou de plusieurs résidus d'acide aminé à l'intérieur de ladite séquence ou de façon adjacente à celle-ci en des positions qui correspondent à celles à l'intérieur du déterminant antigénique ou des déterminants antigéniques de cellule T identifié(s).
  2. Procédé selon la revendication 1, comprenant une étape de soustraction supplémentaire qui élimine dudit second jeu de motifs de cellule T les déterminants antigéniques de cellule T qui sont présents dans des séquences protéines non immunoglobulines humaines en analysant la séquence quant à une similarité par rapport auxdites séquences protéines non immunoglobulines.
  3. Procédé selon la revendication 1 ou 2, dans lequel l'élimination des déterminants antigéniques de cellule T potentiels identifiés par altération d'un ou de plusieurs acides aminés est réalisée par substitution.
  4. Procédé selon la revendication 3, dans lequel les résidus d'acide aminé originaux sont remplacés par des acides aminés de lignée germinale de l'espèce humaine donnée.
  5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la séquence altérée est analysée afin d'identifier de quelconques déterminants antigéniques de cellule T résultant de ladite altération ou d'une altération proposée et est modifiée afin d'éliminer un quelconque tel déterminant antigénique de cellule T, dans lequel l'identification et l'altération sont mises en oeuvre conformément à l'une quelconque des revendications précédentes.
  6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel la molécule de streptokinase désimmunisée comporte la séquence protéine telle que représentée sur la figure 2.
  7. Streptokinase modifiée, qui est non immunogène ou moins immunogène lorsqu'elle est exposée au système immunitaire d'une espèce humaine donnée, comportant la séquence protéine telle que représentée sur la figure 2.
EP98922932A 1997-05-21 1998-05-21 Procede de production de proteines non immunogenes Expired - Lifetime EP0983303B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06004562.2A EP1724282B1 (fr) 1997-05-21 1998-05-21 Procédé de production de protéines non-immunogènes

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB9710480 1997-05-21
GBGB9710480.6A GB9710480D0 (en) 1997-05-21 1997-05-21 Therapeutic immunoglobulins
GBGB9716197.0A GB9716197D0 (en) 1997-07-31 1997-07-31 Therapeutic immunoglobins
GB9716197 1997-07-31
GBGB9725270.4A GB9725270D0 (en) 1997-11-28 1997-11-28 Therapeutic immunoglobulins
GB9725270 1997-11-28
US6723597P 1997-12-02 1997-12-02
US67235P 1997-12-02
GBGB9807751.4A GB9807751D0 (en) 1998-04-14 1998-04-14 Therapeutic immunoglobulins
GB9807751 1998-04-14
PCT/GB1998/001473 WO1998052976A1 (fr) 1997-05-21 1998-05-21 Procede de production de proteines non immunogenes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06004562.2A Division EP1724282B1 (fr) 1997-05-21 1998-05-21 Procédé de production de protéines non-immunogènes

Publications (2)

Publication Number Publication Date
EP0983303A1 EP0983303A1 (fr) 2000-03-08
EP0983303B1 true EP0983303B1 (fr) 2006-03-08

Family

ID=27517404

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98922932A Expired - Lifetime EP0983303B1 (fr) 1997-05-21 1998-05-21 Procede de production de proteines non immunogenes
EP06004562.2A Expired - Lifetime EP1724282B1 (fr) 1997-05-21 1998-05-21 Procédé de production de protéines non-immunogènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06004562.2A Expired - Lifetime EP1724282B1 (fr) 1997-05-21 1998-05-21 Procédé de production de protéines non-immunogènes

Country Status (10)

Country Link
US (2) US7125689B2 (fr)
EP (2) EP0983303B1 (fr)
JP (1) JP2002512624A (fr)
AT (1) ATE319745T1 (fr)
AU (1) AU736549B2 (fr)
CA (1) CA2290485C (fr)
DE (1) DE69833755T2 (fr)
ES (1) ES2258817T3 (fr)
GB (1) GB2339430A (fr)
WO (1) WO1998052976A1 (fr)

Families Citing this family (630)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CN1762492A (zh) 1998-05-23 2006-04-26 莱顿大学医学中心 Cd40结合分子和ctl肽在用于治疗肿瘤的药物组合物中的用途
EP1083922B1 (fr) 1998-06-12 2003-04-09 The Governors Of The University Of Alberta Composition et procede de traitement d'une infection par pseudomonas aeruginosa
CA2342967A1 (fr) * 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
KR20010102978A (ko) 1999-01-15 2001-11-17 아스트루 마이클 제이 면역 질환 치료를 위한 트위크 길항약 및 트위크 수용체길항약 및 이들의 용도
WO2004009618A2 (fr) 2002-07-18 2004-01-29 Crucell Holland B.V. Production par recombinaison de melanges d'anticorps
AU2363301A (en) * 1999-12-02 2001-06-12 Thromb-X N.V. Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
EP1935431A3 (fr) 2000-05-15 2008-08-13 Health Research, Inc. Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2
DE60116753T2 (de) * 2000-05-19 2006-09-14 Scancell Ltd. Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
GB0018901D0 (en) * 2000-08-03 2000-09-20 Biovation Ltd Peptides presented by cells
DK1325033T3 (da) 2000-10-10 2010-04-06 Genentech Inc Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
WO2002062842A1 (fr) * 2001-02-06 2002-08-15 Merck Patent Gmbh Facteur de croissance des keratinocytes modifie (kgf) a immunogenicite reduite
RU2003125638A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный лептин с уменьшенной иммуногенностью
US20040076991A1 (en) * 2001-02-06 2004-04-22 Carr Francis J. Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity
BR0207015A (pt) * 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modificada (epo) com imunogenicidade reduzida
WO2002062832A2 (fr) * 2001-02-06 2002-08-15 Merck Patent Gmbh Facteur neurotrophique bdnf a antigenicite reduite
JP2004527243A (ja) 2001-02-06 2004-09-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾された顆粒球コロニー刺激因子（ｇ−ｃｓｆ）
US7430476B2 (en) * 2001-02-19 2008-09-30 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US7132511B2 (en) * 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
KR20030082962A (ko) * 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
CA2441095A1 (fr) * 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Interferon beta modifie a immunogenicite reduite
JP2004533817A (ja) * 2001-03-20 2004-11-11 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたインスリン
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002098897A2 (fr) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Anticorps modifies diriges contre l'antigene prostatique specifique membranaire et utilisations associees
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7087724B2 (en) * 2001-06-26 2006-08-08 Agen Biomedical Ltd Carrier molecules
RU2004110239A (ru) * 2001-09-04 2005-10-20 Мерк Патент ГмбХ (DE) Модифицированный фактор ix
HUP0402334A3 (en) * 2001-09-04 2007-03-28 Merck Patent Gmbh Modified human growth hormone
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1448602B1 (fr) * 2001-11-12 2010-05-26 MERCK PATENT GmbH Anticorps anti-tnf-alpha modifie
JP2005514026A (ja) * 2001-12-31 2005-05-19 ジェネンコー・インターナショナル・インク 免疫反応の変化を生じるプロテアーゼ、ならびにその製造および利用方法
US7485438B2 (en) * 2002-03-01 2009-02-03 Szu-Yi Chou Method of producing polyvalent antigens
US20030219853A1 (en) * 2002-03-01 2003-11-27 Szu-Yi Chou Method of cross-linking a compound
EP1492819A2 (fr) * 2002-04-09 2005-01-05 MERCK PATENT GmbH Molecules d'anticorps anti-cea anti-idiotypes et leur utilisation comme vaccin contre le cancer
NZ536348A (en) 2002-04-09 2007-05-31 Biogen Idec Inc Use of a TWEAK antagonist for the preparation of a medicament for treating or preventing neurodegeneration
BR0308860A (pt) * 2002-04-18 2005-01-04 Merck Patent Gmbh Fator viii modificado
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1512004T3 (da) * 2002-06-11 2006-06-06 Merck Patent Gmbh Fremgangsmåde til kortlægning og eliminering af T-celleepitoper
WO2003103715A1 (fr) * 2002-06-11 2003-12-18 Merck Patent Gmbh Bryodine 1 modifiee a immunogenicite reduite
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040018568A1 (en) * 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2496789C (fr) 2002-08-28 2013-12-17 Dyax Corp. Procedes de conservation d'organes et de tissus
DK1572748T3 (da) 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
CA2512693A1 (fr) * 2003-01-08 2004-07-29 Xencor, Inc. Nouvelles proteines a pouvoir immunogene modifie
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
EP1606409B1 (fr) 2003-03-19 2010-09-01 Biogen Idec MA Inc. Proteine de liaison de recepteur de nogo
EP1616020A4 (fr) * 2003-03-28 2006-12-27 Jeff Himawan Anticorps anti cr1 a immunogenicite reduite et methodes de traitement les utilisant
ES2368737T3 (es) 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
JP4628357B2 (ja) 2003-04-23 2011-02-09 メダレックス インコーポレイテッド 炎症性腸疾患治療用の組成物及び治療方法
EP2395016A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004108158A1 (fr) * 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. Anticorps anti-cd3 desimmunise
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
EP1641813B1 (fr) * 2003-07-03 2011-11-09 Avatar Biotechnologies, Inc. Procedes d'obtention de molecules presentant une immunogenicite reduite
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR100759745B1 (ko) * 2003-09-10 2007-10-04 에프. 호프만-라 로슈 아게 인터류킨-1 수용체에 대한 항체 및 그의 용도
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20050176028A1 (en) * 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
EP1524275A3 (fr) * 2003-10-16 2005-06-01 Micromet AG Molécules des-immunisées liant le CD3
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
WO2005042581A2 (fr) * 2003-11-01 2005-05-12 Biovation Ltd. Anticorps anti-cd52 modifie
DE602004028270D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
SI1682180T1 (sl) 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
ATE476991T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
CN102344491B (zh) 2003-12-10 2015-03-11 梅达雷克斯有限责任公司 干扰素α抗体及其用途
EP1691837B1 (fr) 2003-12-10 2012-06-20 Medarex, Inc. Anticorps ip-10 et leurs utilisations
EP1706428B1 (fr) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anticorps anticancereux a fixation complementaire reduite
WO2005075647A1 (fr) * 2004-02-06 2005-08-18 Nymox Corporation Anticorps monoclonal anti af-20 humanise
AU2005224942B2 (en) 2004-03-19 2011-08-11 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
CN102603894B (zh) 2004-06-21 2015-09-30 梅达雷克斯有限责任公司 干扰素α受体1抗体及其用途
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
PL2471813T3 (pl) 2004-07-15 2015-09-30 Xencor Inc Zoptymalizowane warianty Fc
CN101014245A (zh) 2004-08-03 2007-08-08 比奥根艾迪克Ma公司 神经元功能中的taj
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (fr) 2004-11-12 2006-05-18 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
WO2006082406A2 (fr) * 2005-02-03 2006-08-10 Antitope Limited Proteines et anticorps humains
EP2529619B1 (fr) 2005-02-17 2015-09-23 Biogen MA Inc. Traitement des troubles neurologiques
WO2006102095A2 (fr) * 2005-03-18 2006-09-28 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
EP1863531A1 (fr) 2005-03-19 2007-12-12 Medical Research Council Ameliorations dans ou concernant le traitement et la prevention d'infections virales
KR101433381B1 (ko) 2005-03-23 2014-10-02 젠맵 에이/에스 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체
WO2006104677A2 (fr) 2005-03-24 2006-10-05 Millennium Pharmaceuticals, Inc. Anticorps se liant a ov064 et leurs methodes d'utilisation
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
WO2006113546A2 (fr) * 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
ZA200709291B (en) 2005-04-25 2009-01-28 Pfizer Antibodies to myostatin
EA012970B1 (ru) 2005-04-26 2010-02-26 Пфайзер Инк. Антитела против р-кадгерина
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
WO2006122187A2 (fr) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
EP1889065B1 (fr) 2005-05-18 2013-07-10 Novartis AG Procédés de diagnostic et de traitement de maladies ayant une composante auto-immune et/ou inflammatoire
CN102441163A (zh) 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2009500390A (ja) * 2005-07-08 2009-01-08 ファイザー・リミテッド 新規ＭＡｄＣＡＭ抗体
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof
WO2007019064A2 (fr) * 2005-08-04 2007-02-15 Centocor, Inc. Anticorps anti-tnf$g(a) et procedes d'utilisation
KR101536506B1 (ko) 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2624189A1 (fr) 2005-10-03 2007-04-12 Xencor, Inc. Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees
EP1940881B1 (fr) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
EP1959979A4 (fr) 2005-11-04 2010-01-27 Biogen Idec Inc Procedes favorisant la croissance des neurites et la survie des neurones dopaminergiques
EP2543384A3 (fr) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Traitement des conditions impliquant la démyélinisation
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
EP2527370A1 (fr) 2005-12-21 2012-11-28 Amgen Research (Munich) GmbH Composés ayant une résistance à CEA soluble
CA2635623C (fr) 2005-12-30 2015-02-17 Michael Super Anticorps anti-cd19 d'immunogenicite reduite
DK1966238T3 (da) * 2005-12-30 2012-07-16 Merck Patent Gmbh INTERLEUKIN-12P40-varianter med forbedret stabilitet
US20070160325A1 (en) * 2006-01-11 2007-07-12 Hyungbin Son Angle-tunable transmissive grating
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
CA2649907A1 (fr) 2006-04-21 2007-11-01 Novartis Ag Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
EP2426150B1 (fr) 2006-06-30 2017-10-25 Novo Nordisk A/S Anticorps anti-NKG2A et leurs utilisations
JP5638804B2 (ja) 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
WO2008042261A2 (fr) 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anticorps anti-charbon, ses formulations, et procédés d'utilisation
PT2486941T (pt) 2006-10-02 2017-05-30 Squibb & Sons Llc Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos
CA2666466C (fr) 2006-10-10 2017-11-14 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Inhibition du complement pour une regeneration amelioree des nerfs
JP2010506839A (ja) 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
EP2530090A3 (fr) 2006-10-19 2013-01-23 CSL Limited Anticorps anti-IL-13R alpha 1 et leurs utilisations
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
EP2395077A1 (fr) 2006-11-03 2011-12-14 Wyeth LLC Substances inhibant la glycolyse dans une culture de cellules
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
CA2671457C (fr) 2006-12-01 2017-09-26 Medarex, Inc. Anticorps humains se liant a cd22 et utilisations de ceux-ci
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2097534A4 (fr) 2006-12-14 2010-05-12 Medarex Inc Anticorps humains se liant à cd70 et utilisations de ceux-ci
DK2426143T3 (en) 2007-01-05 2017-09-11 Univ Zuerich Process for providing disease-specific binding molecules and targets
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2125024B1 (fr) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Administration intracellulaire ciblée d'agents antiviraux
WO2008123999A2 (fr) 2007-04-02 2008-10-16 Amgen Fremont Inc. Anticorps anti-ige
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
DK2167128T3 (da) 2007-07-17 2012-12-03 Merck Patent Gmbh Fremstillede anti-alfa-v-integrin hybrid-antistoffer
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CA2696164C (fr) * 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanises qui se lient a ephb4
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2964398C (fr) 2007-09-14 2023-03-07 Adimab, Llc Bibliotheques d'anticorps synthetiques rationnelles et leurs utilisations
US20100291113A1 (en) 2007-10-03 2010-11-18 Cornell University Treatment of Proliferative Disorders Using Antibodies to PSMA
US8771988B2 (en) 2007-10-12 2014-07-08 Hoffmann-La Roche Inc. Protein expression from multiple nucleic acids
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008320823B2 (en) 2007-11-02 2013-01-17 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
ES2883176T3 (es) * 2007-11-08 2021-12-07 Prec Biologics Inc Anticuerpos monoclonales recombinantes y antígenos correspondientes para cánceres de colon y de páncreas
EP2769993A1 (fr) 2007-12-14 2014-08-27 Novo Nordisk A/S Anticorps contre NKG2D humain et usages correspondants
ES2407603T3 (es) 2007-12-15 2013-06-13 F. Hoffmann-La Roche Ag Ensayo de distinción
CN105418762B (zh) 2007-12-26 2019-11-05 Xencor公司 与FcRn结合改变的Fc变体
US8796427B2 (en) 2008-01-24 2014-08-05 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
EP2650017A3 (fr) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Anticorps Alpha 5 - bêta 1 et leurs utilisations
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
CN102149729B (zh) 2008-04-25 2014-08-20 戴埃克斯有限公司 针对fcrn的抗体及其用途
KR102261586B1 (ko) 2008-06-27 2021-06-08 메뤼스 엔.페. 항체 생산 비-인간 포유동물
EP2315779A2 (fr) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
PE20110225A1 (es) 2008-08-05 2011-04-05 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CA2739357A1 (fr) 2008-09-23 2010-04-08 Wyeth Llc Procedes pour predire la production de signaux d'activation par des proteines de liaison reticulee
CA2740440A1 (fr) 2008-10-14 2010-04-22 Dyax Corp. Utilisation de proteines liant l'igf-ii/igf-iie pour traiter et prevenir la fibrose pulmonaire associee a la sclerose systemique
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
BRPI0923157B1 (pt) 2008-12-19 2021-12-28 University Of Zürich Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
CA2748757A1 (fr) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anticorps anti-lymphotoxine
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
SG173742A1 (en) 2009-03-05 2011-09-29 Medarex Inc Fully human antibodies specific to cadm1
EP2411412B1 (fr) 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Anticorps humanisés dirigés contre le polypeptide light et leurs utilisations
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
CA2759333A1 (fr) 2009-04-22 2010-10-28 Merck Patent Gmbh Proteines de fusion a des anticorps avec des sites de liaison a fcrn modifies
WO2010124113A1 (fr) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anticorps anti-acide gras amide hydrolase 2 et leurs utilisations
KR101836501B1 (ko) 2009-04-27 2018-03-08 노파르티스 아게 근육 성장을 증가시키기 위한 조성물 및 방법
CA2759942A1 (fr) 2009-04-27 2010-10-07 Novartis Ag Composition et procedes d'utilisation d'anticorps therapeutiques specifiques du sous-motif beta-1 des recepteurs d'il-12
DK2448970T3 (da) 2009-05-04 2014-10-06 Abbvie Res B V Antistoffer mod nervevækstfaktor (ngf) med forbedret in vivo-stabilitet
BRPI1013085A2 (pt) 2009-05-13 2020-11-03 Genzyme Corporation imunoglobulinas anti-cd52 humana
CA2764105A1 (fr) 2009-06-08 2010-12-16 Amunix Operating Inc. Polypeptides d'hormone de croissance et leurs procedes de production et d'utilisation
EP2440228B8 (fr) 2009-06-08 2023-02-22 Amunix Operating Inc. Polypeptides de régulation du glucose et leurs procédés de production et d'utilisation
JP2012532846A (ja) 2009-07-09 2012-12-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インビボ腫瘍脈管構造画像処理
WO2011012297A1 (fr) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Traitement enzymatique d'anticorps
EA201270228A1 (ru) 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
WO2011021146A1 (fr) 2009-08-20 2011-02-24 Pfizer Inc. Anticorps contre l'ostéopontine
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
US20120172255A1 (en) 2009-09-07 2012-07-05 Hoffmann-La Roche, Inc, Es-ms of glycopeptides for analysis of glycosylation
WO2011029823A1 (fr) 2009-09-09 2011-03-17 Novartis Ag Anticorps monoclonal réactif avec cd63 lors de son expression à la surface de mastocytes dégranulés
EP2470569A1 (fr) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Anticorps anti-epha10
SG10201407757XA (en) 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
NZ599761A (en) 2009-11-04 2014-04-30 Merck Sharp & Dohme Engineered anti-tslp antibody
CA2778552A1 (fr) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Traitement d'un cancer caracterise par la mutation des genes kras ou braf
AU2010329934B2 (en) 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
SG181893A1 (en) 2009-12-22 2012-08-30 Hoffmann La Roche Sequence dependent aggregation
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
MX336682B (es) 2010-03-05 2016-01-27 Hoffmann La Roche Anticuerpos contra csf-1r humanos y usos de los mismos.
MX2012010728A (es) 2010-03-17 2013-03-05 Abbott Res Bv Composiciones de anticuerpos de factor de anti-crecimiento de nervios (ngf).
EP4450523A2 (fr) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
KR20130066632A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
WO2011149461A1 (fr) 2010-05-27 2011-12-01 Medtronic, Inc. Anticorps anti-amyloïde bêta conjugués à des molécules contenant de l'acide sialique
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
TW201244719A (en) 2010-07-09 2012-11-16 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012007880A2 (fr) 2010-07-16 2012-01-19 Ablynx Nv Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations
WO2012019061A2 (fr) 2010-08-05 2012-02-09 Stem Centrx, Inc. Nouveaux effecteurs et leurs procédés d'utilisation
EP2420250A1 (fr) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anticorps anti-syndecan-4
CN105037552B (zh) 2010-08-20 2019-03-29 诺华股份有限公司 表皮生长因子受体3（her3)的抗体
AU2011293127B2 (en) 2010-08-27 2016-05-12 Abbvie Stemcentrx Llc Notum protein modulators and methods of use
NZ608814A (en) 2010-09-03 2015-06-26 Stem Centrx Inc Novel modulators and methods of use
CA2811644C (fr) 2010-09-29 2022-07-12 Agensys, Inc. Conjugues anticorps-medicaments (adc) se liant aux proteines 191p4d12
WO2012045703A1 (fr) 2010-10-05 2012-04-12 Novartis Ag Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
KR101584416B1 (ko) 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 인간 tweak에 대한 항체 및 그의 용도
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
EA029419B1 (ru) 2010-11-19 2018-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Нейтрализующие антитела против ccl20
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
EP2471543A1 (fr) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction de tolérance ou immunosuppression pour empêcher en particulier la réaction du greffon contre l'hôte (GvHD) par une pré-incubation de courte durée des suspensions de cellules transplantées, tissus ou organes revêtus par les ligands sur les molécules à la surface des cellules
CA2818635C (fr) 2010-12-06 2021-06-15 National Reseach Council Of Canada Anticorps selectifs pour des cellules presentant erbb2 a une densite elevee
SG191081A1 (en) 2010-12-08 2013-07-31 Stem Centrx Inc Novel modulators and methods of use
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
ES2860748T3 (es) 2011-01-24 2021-10-05 Gilead Sciences Inc Anticuerpos selectivos para células que presentan EGFR con alta densidad
EP3263125A3 (fr) 2011-02-02 2018-03-14 Emory University Antagonisme de la voie de signalisation vip
SG192667A1 (en) 2011-02-11 2013-09-30 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of prostate cancer
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012119989A2 (fr) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Procédés et anticorps pour le diagnostic et le traitement du cancer
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
EP2952210A3 (fr) 2011-04-07 2016-03-16 Emory University Compositions comprenant des fractions de liaison de saccharide et procédés destinés à une thérapie ciblée
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
ES2657862T3 (es) 2011-05-13 2018-03-07 Gamamabs Pharma Anticuerpos contra HER3
EP2714738B1 (fr) 2011-05-24 2018-10-10 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
SG10201604493TA (en) 2011-06-02 2016-07-28 Dyax Corp Fc RECEPTOR BINDING PROTEINS
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
WO2012172495A1 (fr) 2011-06-14 2012-12-20 Novartis Ag Compositions et procédés de ciblage du tem8 par des anticorps
CA2839508A1 (fr) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps anti-axl et utilisations associees
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20150158934A1 (en) 2011-09-09 2015-06-11 Ucl Business Plc Broadly neutralizing vhh against hiv-1
JP6216317B2 (ja) 2011-09-09 2017-10-18 メディミューン リミテッド 抗Ｓｉｇｌｅｃ−１５抗体およびその使用
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
CA2849409A1 (fr) * 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Agents du facteur de necrose tumorale alpha et utilisations de ceux-ci
CA2791109C (fr) 2011-09-26 2021-02-16 Merus B.V. Generation de molecules de liaison
PE20142361A1 (es) 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
ES2548215T3 (es) 2011-10-05 2015-10-14 F. Hoffmann-La Roche Ag Proceso para la producción de anticuerpos de la glicoforma G1
EP2766033B1 (fr) 2011-10-14 2019-11-20 Novartis AG Anticorps et méthodes pour traiter des maladies associées à la voie de signalisation wnt
WO2013067060A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067055A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Procédés de blocage de la croissance des cellules souches cancéreuses
WO2013067057A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
US20140286959A1 (en) 2011-11-08 2014-09-25 Pfizer Inc. Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA029602B1 (ru) 2011-11-29 2018-04-30 Проклара Байосайенсиз, Инк. Применение белков р3 бактериофага в качестве агентов, связывающих амилоид
KR102218497B1 (ko) 2011-12-05 2021-02-22 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN107353342B (zh) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
PE20150159A1 (es) 2011-12-21 2015-02-08 Novartis Ag Composiciones y metodos para anticuerpos que actuan sobre el factor p
WO2013096948A1 (fr) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulines et variants dirigés contre des microbes pathogènes
WO2013092998A1 (fr) 2011-12-23 2013-06-27 Innate Pharma Conjugaison enzymatique d'anticorps
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
AU2013207927B2 (en) 2012-01-10 2017-11-02 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
SI2814840T1 (sl) 2012-02-15 2020-06-30 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njihove izdelave in uporabe
WO2013123457A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Protéines de facteur viii de recombinaison
CN104334580B (zh) 2012-02-24 2018-03-30 艾伯维施特姆森特克斯有限责任公司 抗sez6抗体及使用方法
ME02928B (fr) 2012-02-24 2018-04-20 Abbvie Stemcentrx Llc Modulateurs de dll3 et leurs procédés d'utilisation
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013128027A1 (fr) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Molécules de liaison à un polypeptide à longue durée de vie
CN110317259A (zh) 2012-03-27 2019-10-11 株式会社绿十字 表皮生长因子受体表面抗原的表位及其用途
RS59260B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
EP2847216A1 (fr) 2012-05-07 2015-03-18 Sanofi Méthodes permettant d'empêcher la formation de biofilms
WO2013173364A2 (fr) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
WO2013175276A1 (fr) 2012-05-23 2013-11-28 Argen-X B.V Molécules se liant à l'il-6
WO2013176756A1 (fr) * 2012-05-25 2013-11-28 Bayer Healthcare Llc Système et procédé de prédiction de l'immunogénicité d'un peptide
US20150104468A1 (en) 2012-06-04 2015-04-16 Irm Llc Site-specific labeling methods and molecules produced thereby
US20140162949A1 (en) 2012-06-05 2014-06-12 Amunix Operating Inc. Treatment with human growth hormone analogues
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
WO2014016737A1 (fr) 2012-07-24 2014-01-30 Pfizer Inc. Nouveaux anticorps monoclonaux de poulet dirigés contre la protéine tau phosphorylée humaine et leurs utilisations
EP2887959B1 (fr) 2012-08-23 2018-12-19 Agensys, Inc. Conjugués de médicaments anticorps (adc) qui se lient aux protéines 158p1d7
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
EP3564259A3 (fr) 2012-11-09 2020-02-12 Innate Pharma Étiquettes de reconnaissance pour la conjugaison à médiation par la tgase
EP2733153A1 (fr) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour la préparation d'immunoconjugués et leurs utilisations
WO2014084859A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Molécules et procédés pour la modulation d'activités de tmem16a
CN109517063B (zh) 2012-12-05 2022-07-01 诺华股份有限公司 靶向epo的抗体的组合物和方法
WO2014087299A1 (fr) 2012-12-07 2014-06-12 Pfizer Inc. Fragments d'anticorps monomérique génétiquement modifié
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
JP6490591B2 (ja) 2012-12-10 2019-03-27 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗血液樹状細胞抗原２抗体およびその使用
HUE051320T2 (hu) 2012-12-21 2021-05-28 Biogen Ma Inc Humán anti-TAU antitestek
CA2896331C (fr) 2012-12-26 2023-08-01 Oncosynergy, Inc. Compositions d'anticorps anti-integrine .beta.1 et leurs procedes d'utilisation
EP2938631B1 (fr) 2012-12-31 2018-12-19 Neurimmune Holding AG Anticorps humains recombinants pour la thérapie et la prévention de maladies associées au virus du polyome
MA37407B1 (fr) 2013-02-04 2018-03-30 Sanofi Sa Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
WO2015198217A2 (fr) 2013-02-08 2015-12-30 Novartis Ag Compositions et procédés pour anticorps à longue durée d'action ciblant l'il-17
HUE054443T2 (hu) 2013-02-08 2021-09-28 Novartis Ag Ellenanyagok módosítására, ezáltal immunkonjugátumok elõállítására szolgáló specifikus helyek
WO2014124258A2 (fr) 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
CA2897682C (fr) 2013-02-08 2023-03-14 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
DK2958944T3 (da) 2013-02-22 2019-06-24 Abbvie Stemcentrx Llc Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970479B1 (fr) 2013-03-14 2019-04-24 Novartis AG Anticorps dirigés contre notch 3
ES2701051T3 (es) 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
CA2907181C (fr) 2013-03-15 2023-10-17 Viktor Roschke Complexes multispecifiques multivalents et monovalents et leurs utilisations
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
EP2968450A4 (fr) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Toxines modifiées
JP6397886B2 (ja) 2013-03-15 2018-09-26 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
US9543183B2 (en) * 2013-04-01 2017-01-10 Fm Industries, Inc. Heated electrostatic chuck and semiconductor wafer heater and methods for manufacturing same
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014186877A1 (fr) 2013-05-24 2014-11-27 Uger Marni Diane Anticorps dirigés contre le récepteur fas à usage diagnostique et thérapeutique
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EP3010548A1 (fr) 2013-06-21 2016-04-27 Innate Pharma Conjugaison enzymatique de polypeptides
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
CA2919701A1 (fr) 2013-08-01 2015-02-05 Agensys, Inc. Conjugues anticorps-medicament (adc) se liant a la proteine cd37
WO2015015401A2 (fr) 2013-08-02 2015-02-05 Pfizer Inc. Anticorps anti-cxcr4 et conjugués anticorps-médicaments
EP2832854A1 (fr) 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Méthode d'amélioration de l'expression d'une polypeptide par la fusion C-terminale avec neprilysin humaine
CN104341502B (zh) * 2013-08-09 2016-04-27 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α全人源单抗及其应用
PE20160244A1 (es) 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
EP3033358A2 (fr) 2013-08-14 2016-06-22 Novartis AG Traitement de la myosite corps d'inclusion sporadique
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CN105792836A (zh) 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
KR20160044042A (ko) 2013-08-28 2016-04-22 스템센트알엑스 인코포레이티드 부위-특이적 항체 접합 방법 및 조성물
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
DK3060908T3 (da) 2013-10-21 2021-05-25 Dyax Corp Diagnosticering og behandling af autoimmune sygdomme
ES2865196T3 (es) 2013-11-07 2021-10-15 Inst Nat Sante Rech Med Anticuerpos anti-HER3 humana alostéricos de neuregulina
EP3077504B1 (fr) 2013-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
CN106459187A (zh) 2013-12-09 2017-02-22 纽约大学 用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法
EP3954714A1 (fr) 2014-01-08 2022-02-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Polypeptides de fusion et leurs méthodes d'utilisation
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
JP2017509337A (ja) 2014-03-12 2017-04-06 ノバルティス アーゲー イムノコンジュゲートを作製する抗体を修飾するための特定部位
CA2939006A1 (fr) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Compositions vaccinales et methodes pour retablir la fonction de la voie nkg2d contre les cancers
CN106164094B (zh) 2014-03-21 2021-05-14 X博迪公司 双特异性抗原结合多肽
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
ES2783376T3 (es) 2014-04-25 2020-09-17 Rinat Neuroscience Corp Conjugados de anticuerpo-fármaco con alta carga de fármaco
EP3143137A4 (fr) 2014-05-14 2017-11-15 Trustees of Dartmouth College Lysostaphine désimmunisée et méthodes d'utilisation
WO2015173756A2 (fr) 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
SG11201610074YA (en) 2014-06-06 2016-12-29 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10357472B2 (en) 2014-06-12 2019-07-23 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
US10799582B2 (en) 2014-07-11 2020-10-13 Iogenetics, Llc Immunoglobulin polypeptide fractions from products of domestic animals
EP3174898A2 (fr) 2014-07-29 2017-06-07 Neurimmune Holding AG Anticorps anti-huntingtine (htt) humains et leurs utilisations
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
MX2017001401A (es) 2014-07-31 2017-08-07 Amgen Res (Munich) Gmbh Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
JP6698065B2 (ja) 2014-07-31 2020-05-27 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 組織分布が向上した二重特異性単鎖抗体コンストラクト
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TN2016000577A1 (en) 2014-08-12 2018-04-04 Novartis Ag Anti-cdh6 antibody drug conjugates
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
TWI790593B (zh) 2014-08-19 2023-01-21 美商默沙東有限責任公司 抗tigit抗體
PL3185908T3 (pl) 2014-08-28 2020-09-07 Pfizer Inc. Łączniki modulujące stabilność do stosowania z koniugatami przeciwciało-lek
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
WO2016043788A1 (fr) 2014-09-16 2016-03-24 United Biomedical, Inc Traitement et guérison fonctionnelle de l'infection par le vih par des anticorps monoclonaux cd4 médiant une inhibition compétitive d'une entrée du vih
US10392447B2 (en) 2014-09-30 2019-08-27 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
RU2020126237A (ru) 2014-11-19 2020-12-01 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
WO2016087514A1 (fr) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anticorps anticalréticuline mutante et leur utilisation dans le diagnostic et la thérapie de tumeurs malignes myéloïdes
AU2015358504A1 (en) 2014-12-03 2017-06-29 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
CA2874083C (fr) 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3945096A1 (fr) 2014-12-19 2022-02-02 Regenesance B.V. Anticorps qui se lient au c6 humain et leurs utilisations
CA2971732A1 (fr) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Anticorps contre tigit
WO2016112270A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CA2916283A1 (fr) 2015-01-09 2016-07-09 Pfizer Inc. Regime de dosage pour antagonistes de madcam
SG11201708438WA (en) 2015-04-17 2017-11-29 Amgen Res (Munich) Gmbh Bispecific antibody constructs for cdh3 and cd3
WO2016187068A1 (fr) 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du récepteur du facteur de nécrose anti-tumoral
JP6770533B2 (ja) 2015-05-22 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃａｔｈ−Ｄの触媒活性と、そのＬＲＰ１レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
WO2016191246A2 (fr) 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center Anticorps semblables aux récepteurs de lymphocytes t spécifiques pour un peptide prame
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
US10047155B2 (en) 2015-06-05 2018-08-14 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
EP3310813A1 (fr) 2015-06-17 2018-04-25 Novartis AG Conjugués anticorps-médicament
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3313886A1 (fr) 2015-06-29 2018-05-02 The Rockefeller University Anticorps anti-cd40 présentant une activité agoniste renforcée
US20180201687A1 (en) 2015-07-07 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
EP3957654A1 (fr) 2015-07-15 2022-02-23 Prosit Sole Biotechnology (Beijing) Co., Ltd Polypeptides de fusion et leurs procédés d'utilisation
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
CA2994412A1 (fr) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Proteines de liaison d'antigene ciblant cd56 et leurs utilisations
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CA2994825A1 (fr) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anticorps anti-cd154 et procedes d'utilisation correspondant
AU2016316730B2 (en) 2015-09-02 2023-05-25 Immutep S.A.S. Anti-LAG-3 Antibodies
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
PL3347377T3 (pl) 2015-09-09 2021-07-19 Novartis Ag Przeciwciała wiążące limfopoetynę zrębu grasicy (tslp) i sposoby zastosowania tych przeciwciał
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
UA126896C2 (uk) 2015-11-03 2023-02-22 Янссен Байотек, Інк. Антитіло, що специфічно зв’язується з pd-1, і спосіб його застосування
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN108602885B (zh) 2015-11-30 2022-05-24 百时美施贵宝公司 抗人ip-10抗体及其用途
CA3006477A1 (fr) 2015-12-04 2017-06-08 Novartis Ag Compositions a greffe de cytokine-anticorps et procedes d'utilisation pour l'immunoregulation
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
CN108713027A (zh) 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途
RU2018126297A (ru) 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
CN109069627A (zh) 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 对foxp3衍生肽特异性的t细胞受体样抗体
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
FI3411404T3 (fi) 2016-02-03 2023-01-31 T-soluja aktivoivia psma- ja cd3-bispesifisisiä vasta-ainekonstrukteja
EA039594B1 (ru) 2016-02-03 2022-02-15 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
JP2019513008A (ja) 2016-02-26 2019-05-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂｔｌａに対して特異性を有する抗体及びその使用
IL261602B2 (en) 2016-03-04 2024-06-01 Univ Rockefeller CD40 antibodies with increased agonistic activity
CA3016187A1 (fr) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Polytherapie avec des anticorps anti-cd73
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CA3019588A1 (fr) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Proteines de liaison a un antigene de neutralisation des cmv
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR20190079713A (ko) 2016-06-13 2019-07-05 아이-맵 항-pd-l1 항체 및 이것의 사용
CN110381988A (zh) 2016-06-15 2019-10-25 诺华股份有限公司 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030765A1 (fr) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Anticorps anti-tim3 et leurs utilisations
MA45715A (fr) 2016-07-25 2019-05-29 Biogen Ma Inc Anticorps anti-hspa5 (grp78) et leurs utilisations
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
BR112019001693A2 (pt) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse anticorpos direcionados a macrófagos associados a tumores e seus usos
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
AU2017312887A1 (en) 2016-08-13 2019-03-07 United BioPharma, Inc. Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
WO2018035710A1 (fr) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
WO2018036852A1 (fr) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Dosage intermittent d'un anticorps anti-csf-1r en combinaison avec un agent d'activation de macrophages
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
NZ750976A (en) 2016-09-19 2023-01-27 I Mab Biopharma Hangzhou Co Ltd Anti-gm-csf antibodies and uses thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
CU20210030A7 (es) 2016-10-13 2021-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
KR20190084264A (ko) 2016-10-25 2019-07-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd160 막 횡단 동형체에 결합하는 단클론 항체
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
MX2019007411A (es) 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
AU2017384276B9 (en) 2016-12-21 2020-11-26 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
EP3558360A1 (fr) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Traitement de tumeurs par un anticorps anti-csf1r en association avec un anticorps anti-pd-l1 après l'échec d'un traitement anti-pd-l1/pd1
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
BR112019013238A2 (pt) 2017-01-20 2020-02-11 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorpos anti-pd-1 e usos dos mesmos
KR20200108915A (ko) 2017-01-24 2020-09-21 아이-맵 바이오파마 유에스 리미티드 항-cd73 항체 및 이것의 사용
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
WO2018158398A1 (fr) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps présentant une spécificité pour la nectine-4 et leurs utilisations
CN110461359A (zh) 2017-03-24 2019-11-15 诺华股份有限公司 用于预防和治疗心脏病的方法
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
US11421032B2 (en) 2017-05-22 2022-08-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of MICA/B shedding
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer
WO2018226580A2 (fr) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
RU2019143078A (ru) 2017-06-28 2021-07-28 Новартис Аг Способы предупреждения и лечения недержания мочи
WO2019057933A1 (fr) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Anticorps présentant une spécificité pour btn2 et leurs utilisations
CA3076611A1 (fr) * 2017-09-23 2019-03-28 Memorial Sloan Kettering Cancer Center Compositions d'anticorps a33 et leurs methodes d'utilisation en radioimmunotherapie
EP3694552A1 (fr) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anticorps anti-lap et leurs utilisations
EP3700933A1 (fr) 2017-10-25 2020-09-02 Novartis AG Anticorps ciblant cd32b et leurs procédés d'utilisation
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
JP2021508439A (ja) 2017-12-01 2021-03-11 ノバルティス アーゲー ポリオーマウイルス中和抗体
JP7344206B2 (ja) 2017-12-11 2023-09-13 アムジェン インコーポレイテッド 二重特異性抗体製品のための連続製造プロセス
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
BR112020013405A2 (pt) 2018-01-25 2020-12-01 Acm Biolabs Pte Ltd. polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
MX2020009861A (es) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
EP3775909B1 (fr) 2018-03-26 2023-05-10 Glycanostics s.r.o. Moyens et procédés de glycoprofilage d'une protéine
RU2020135052A (ru) 2018-03-28 2022-04-29 Аксон Ньюросайенс Се Способы выявления и лечения болезни альцгеймера на основе антител
US11471506B2 (en) 2018-04-23 2022-10-18 Emory University VIP antagonists and uses in treating cancer
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2019222682A1 (fr) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
HRP20240975T1 (hr) * 2018-05-23 2024-10-25 Pfizer Inc. Protutijela specifična za cd3 i njihova upotreba
AU2019274652A1 (en) 2018-05-24 2020-11-26 Janssen Biotech, Inc. Monospecific and multispecific anti-TMEFF2 antibodies and there uses
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CN112165974B (zh) 2018-05-31 2024-11-08 诺华股份有限公司 乙型肝炎抗体
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
TW202021616A (zh) 2018-07-30 2020-06-16 美商安進公司 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
KR20210042117A (ko) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Cldn18.2 및 cd3에 대한 항체 작제물
KR102666754B1 (ko) 2018-08-21 2024-05-17 에이비엘바이오 주식회사 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
US20220105176A1 (en) 2018-09-12 2022-04-07 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
CN112789058A (zh) 2018-10-11 2021-05-11 安进公司 双特异性抗体构建体的下游加工
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020080941A1 (fr) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anticorps anti-protéine 5/6 associée au récepteur de lipoprotéines de faible densité
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CA3119838A1 (fr) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anticorps anti-nkg2a et leurs utilisations
US20220056136A1 (en) 2018-11-30 2022-02-24 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2020130838A2 (fr) 2018-12-21 2020-06-25 Qvq Holding B.V. Anticorps pour la prévention ou le traitement de la candidose
CA3234463A1 (fr) 2018-12-21 2019-12-18 Novartis Ag Anticorps diriges contre pmel17 et conjugues de ces derniers
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
EP3914622A1 (fr) 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Anticorps contre la sous-unité alpha d'un l'il-7r et leurs utilisations
SG11202108560RA (en) 2019-02-13 2021-09-29 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof
EP3928790A4 (fr) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Fragment de liaison à l'antigène cd3 et application de celui-ci
EP3941940A1 (fr) 2019-03-20 2022-01-26 Imcheck Therapeutics SAS Anticorps ayant une spécificité pour btn2 et leurs utilisations
EP3947446A1 (fr) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Traitement de troubles de tauopathie par ciblage de nouvelles espèces tau
CN113939534A (zh) 2019-04-03 2022-01-14 建新公司 具有降低的断裂的抗αβTCR结合多肽
SG11202112056PA (en) 2019-05-20 2021-12-30 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
AU2020279731A1 (en) 2019-05-20 2022-01-06 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
WO2020234399A1 (fr) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveaux anticorps anti-cd25
AU2020279224A1 (en) 2019-05-21 2021-12-16 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
US11066469B2 (en) 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
CA3137494A1 (fr) 2019-06-13 2020-12-17 Amgen Inc. Commande de perfusion contenant de la biomasse automatisee dans la fabrication de produits biologiques
US20220324932A1 (en) 2019-06-20 2022-10-13 CSPC Megalith Biopharmaceutical Co., Ltd. Modified il-2 proteins, peg conjugates, and uses thereof
EP4026846A4 (fr) 2019-09-03 2023-09-13 Bio-Thera Solutions, Ltd. Immunosuppresseur anti-tigit et son application
EP4028416A1 (fr) 2019-09-10 2022-07-20 Amgen Inc. Procédé de purification de polypeptides de liaison à un antigène bispécifique présentant une capacité de liaison dynamique de capture de protéine l améliorée
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021058729A1 (fr) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
EP4034560A1 (fr) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps de de substance inhibitrice müllérienne et leurs utilisations
CA3154710A1 (fr) 2019-10-04 2021-04-08 TAE Life Sciences Compositions d'anticorps comprenant des mutations de fc et ayant des proprietes de conjugaison specifiques a un site
KR20220131221A (ko) 2019-11-13 2022-09-27 아뮤닉스 파마슈티컬스, 인크. 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP3825330A1 (fr) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anticorps anti-cd117 et leurs procédés d'utilisation
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
EP4081554A1 (fr) 2019-12-27 2022-11-02 Affimed GmbH Procédé de production de construction d'anticorps bispécifique fcyriii x cd30
EP4093771A1 (fr) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations
MX2022010665A (es) 2020-02-27 2022-09-23 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
WO2021175954A1 (fr) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Anticorps ayant une spécificité pour btnl8 et leurs utilisations
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
EP4121459A1 (fr) 2020-03-19 2023-01-25 Amgen Inc. Anticorps contre la mucine 17 et leurs utilisations
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
EP4130035A4 (fr) 2020-03-31 2024-06-26 Bio-Thera Solutions, Ltd. Anticorps et protéine de fusion pour traiter des coronavirus et leur utilisation
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN115996951A (zh) 2020-04-30 2023-04-21 赛罗帕私人有限公司 抗cd103抗体
EP3909601A1 (fr) 2020-05-11 2021-11-17 LeukoCom GmbH Nouvel anticorps se liant spécifiquement au ceacam 1/3/5 humain et son utilisation
JP2023525826A (ja) 2020-05-12 2023-06-19 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｓｔ２抗原結合タンパク質
WO2021228956A1 (fr) 2020-05-12 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau procédé de traitement de lymphomes cutanés à lymphocytes t et de lymphomes dérivés de tfh
WO2021236638A1 (fr) 2020-05-19 2021-11-25 Amgen Inc. Constructions de liaison à mageb2
EP3915641A1 (fr) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anticorps anti-cd5 et leurs procédés d'utilisation
WO2021243320A2 (fr) 2020-05-29 2021-12-02 Amgen Inc. Administration atténuant des effets indésirables d'une construction d'anticorps bispécifique de liaison à cd33 et cd3
US20230287126A1 (en) 2020-08-07 2023-09-14 Bio-Thera Solutions, Ltd. Anti-pd-l1 antibody and use thereof
WO2022056318A1 (fr) * 2020-09-10 2022-03-17 Brickbio, Inc. Anticorps contenant des acides aminés non naturels et procédés de fabrication et d'utilisation de ceux-ci
EP4225792A1 (fr) 2020-10-08 2023-08-16 Affimed GmbH Lieurs trispécifiques
TW202233678A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增強的剪切特徵的多肽
US20240067728A1 (en) 2020-11-06 2024-02-29 Bio-Thera Solutions, Ltd. Bispecific antibody and use thereof
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
EP4240768A2 (fr) 2020-11-06 2023-09-13 Amgen Inc. Molécules bispécifiques multicibles de liaison à un antigène à sélectivité accrue
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
AU2021375733A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs binding to cd3
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 選擇性地與cldn6和cd3結合的多肽構建體
JP2023547506A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
JP2024504547A (ja) 2020-11-20 2024-02-01 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 抗ｃｄ２５抗体
EP4247497A1 (fr) 2020-11-20 2023-09-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Anticorps anti-cd25
EP4251648A2 (fr) 2020-11-24 2023-10-04 Novartis AG Anticorps anti-cd48, conjugués anticorps-médicament et leurs utilisations
EP4251208A1 (fr) 2020-11-24 2023-10-04 Novartis AG Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
WO2022143794A1 (fr) 2020-12-30 2022-07-07 百奥泰生物制药股份有限公司 Anticorps anti-cldn18.2, son procédé de préparation et son utilisation
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
EP4284838A2 (fr) 2021-01-28 2023-12-06 Janssen Biotech, Inc. Protéines de liaison à psma et leurs utilisations
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
BR112023021224A2 (pt) 2021-04-12 2024-01-16 Acm Biolabs Pte Ltd Polimerossomas compreendendo polinucleotídeo encapsulado solúvel e lipídio ionizável, bem como métodos de produção e usos dos mesmos
EP4323526A1 (fr) 2021-04-16 2024-02-21 Novartis AG Conjugués anticorps-médicament et leurs procédés de fabrication
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
TW202317626A (zh) 2021-06-18 2023-05-01 大陸商正大天晴藥業集團股份有限公司 抗il-36r抗體及其用途
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
WO2023046037A1 (fr) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 Anticorps anti-cd40 et son utilisation
WO2023051663A1 (fr) 2021-09-30 2023-04-06 百奥泰生物制药股份有限公司 Anticorps anti-b7-h3 et son utilisation
US11542340B1 (en) 2021-10-29 2023-01-03 Biodesix, Inc. Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a
MX2024005397A (es) 2021-11-03 2024-05-23 Affimed Gmbh Agentes de union a cd16a biespecificos.
TW202323285A (zh) 2021-11-05 2023-06-16 大陸商正大天晴藥業集團股份有限公司 抗cldn18.2抗體及其用途
EP4438055A1 (fr) 2021-11-25 2024-10-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anticorps anti-siglec-15 et son utilisation
EP4455164A1 (fr) 2021-12-24 2024-10-30 Bio-Thera Solutions, Ltd. ANTICORPS ANTI-FRalpha, CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION
KR20240155347A (ko) 2022-03-09 2024-10-28 알데란 바이오테크놀로지 항-cd160 막관통 동형 항체
AU2022446336A1 (en) 2022-03-18 2024-09-19 Beijing Mabworks Biotech Co., Ltd B7-h3-binding antibody and use thereof
AU2023240297A1 (en) 2022-03-22 2024-10-03 Morphosys Ag Deimmunized antibodies specific for cd3
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023222886A1 (fr) 2022-05-20 2023-11-23 Depth Charge Ltd Protéines de fusion anticorps-cytokine
WO2024052503A1 (fr) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
WO2024056668A1 (fr) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale Nouveaux anticorps anti-itgb8 et leurs utilisations
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024096735A1 (fr) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Anticorps anti-cd169 à domaine unique
WO2024101989A1 (fr) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Récepteurs d'antigènes inductibles par activation pour immunothérapie adoptive
EP4406973A1 (fr) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Anticorps et leurs utilisations pour le traitement d'infections provoquées par des virus enveloppés
US20240327538A1 (en) 2023-02-10 2024-10-03 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen and methods for making and using the same
WO2024187062A1 (fr) 2023-03-08 2024-09-12 Amgen Inc. Processus de lyophilisation par nucléation à glace contrôlée pour des molécules bispécifiques
WO2024206738A1 (fr) 2023-03-31 2024-10-03 Immunai Inc. Anticorps anti-trem2 humanisés
WO2024220397A1 (fr) 2023-04-17 2024-10-24 Amunix Pharmaceuticals, Inc. Compositions ciblant le récepteur du facteur de croissance épidermique et leurs procédés de fabrication et d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (fr) 1990-01-19 1991-07-24 Merck & Co. Inc. Méthode de production d'immunoglobulines recombinantes
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
CA2507749C (fr) * 1991-12-13 2010-08-24 Xoma Corporation Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ATE290598T1 (de) * 1995-01-06 2005-03-15 Leuven Res & Dev Vzw Neue staphylokinase derivate

Also Published As

Publication number Publication date
CA2290485A1 (fr) 1998-11-26
US7465572B2 (en) 2008-12-16
DE69833755D1 (de) 2006-05-04
EP1724282A2 (fr) 2006-11-22
JP2002512624A (ja) 2002-04-23
US20070014796A1 (en) 2007-01-18
EP0983303A1 (fr) 2000-03-08
EP1724282B1 (fr) 2013-05-15
ES2258817T3 (es) 2006-09-01
DE69833755T2 (de) 2006-12-28
CA2290485C (fr) 2008-08-05
AU7539398A (en) 1998-12-11
GB9925632D0 (en) 1999-12-29
ATE319745T1 (de) 2006-03-15
GB2339430A (en) 2000-01-26
GB2339430A8 (en) 2000-01-31
AU736549B2 (en) 2001-08-02
WO1998052976A1 (fr) 1998-11-26
US7125689B2 (en) 2006-10-24
US20030153043A1 (en) 2003-08-14
EP1724282A3 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
EP0983303B1 (fr) Procede de production de proteines non immunogenes
EP1051432B1 (fr) Modification de l'immunogenicite de proteines
JP3491896B2 (ja) 免疫調節ペプチド
JPH08502244A (ja) 免疫調節ペプチド
JP3220451B2 (ja) ブタクサからのアレルゲン蛋白質およびそれらの使用
US5171674A (en) Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
JP2004502403A (ja) アルファ−２−マクログロブリン様ポリペプチドおよびポリヌクレオチドに関する方法と材料
KR100465382B1 (ko) 말라세지아에서 유래된 항원성 단백질
JP2004502405A (ja) トランスフォ−ミング成長因子アルファｔｇｆアルファ様ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2002543761A (ja) 結核症抗原およびそのための使用の方法
US5698204A (en) Recombinant allergenic proteins from ragweed pollen
US5215963A (en) Solubilization and purification of the active gastrin releasing peptide receptor
Schoel et al. Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I‐restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein
JP2004500120A (ja) インスリン様増殖因子結合タンパク質様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US6222010B1 (en) Urogenital carcinoma TLP peptides
JP2004500081A (ja) ロイシン・リッチ反復蛋白質様（ｌｒｒ蛋白質様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
WO1990000606A1 (fr) Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire
JP2004500078A (ja) 癌胎児抗原様（ｃｅａ様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004518410A5 (fr)
JP2004524001A (ja) 白血球免疫グロブリン受容体（ｌｉｒ様）ポリペプチドおよびポリヌクレオチドに関する方法と材料
JP2004515207A (ja) メタロカルボキシペプチダーゼ様ポリペプチドおよびポリヌクレオチドに関する方法と材料
JPH1132783A (ja) Ｈｆｉｚｇ５３ポリヌクレオチドおよびポリペプチド
JP2003289887A (ja) 免疫調節ペプチド
JP2002535966A (ja) 超抗原
JP2004515206A (ja) 新規なヴォン・ヴィレブランド／トロンボスポンジン様ポリペプチドおよびポリヌクレオチドに関連する方法および材料

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991206;LT PAYMENT 19991206;LV PAYMENT 19991206;MK PAYMENT 19991206;RO PAYMENT 19991206;SI PAYMENT 19991206

17Q First examination report despatched

Effective date: 20000904

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ADAIR, FIONA, SUZANNEBIOVATION LIMITED

Inventor name: HAMILTON, ANITA, ANNE,BIOVATION LIMITED

Inventor name: CARTER, GRAHAM,BIOVATION LIMITED

Inventor name: CARR, FRANCIS, JOSEPH

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69833755

Country of ref document: DE

Date of ref document: 20060504

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060608

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060808

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20060308

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2258817

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20061211

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060308

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120516

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120516

Year of fee payment: 15

Ref country code: FR

Payment date: 20120608

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120519

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120607

Year of fee payment: 15

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69833755

Country of ref document: DE

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130521

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130522